×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RCKT – rocket pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RCKT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/19
05:41 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $39.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $39.00 price target on the stock.
11/19
02:49 pm
rckt
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst [Yahoo! Finance]
Low
Report
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst [Yahoo! Finance]
11/19
11:09 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at Leerink Partners from $46.00 to $44.00. They now have an "outperform" rating on the stock.
Low
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its price target lowered by analysts at Leerink Partners from $46.00 to $44.00. They now have an "outperform" rating on the stock.
11/19
09:31 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $65.00 price target on the stock.
11/19
08:20 am
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $52.00 price target on the stock.
11/19
08:20 am
rckt
2024 BioTech Breakthrough Awards Program Celebrates Groundbreaking Biotechnology Innovators Around the World [Yahoo! Finance]
Medium
Report
2024 BioTech Breakthrough Awards Program Celebrates Groundbreaking Biotechnology Innovators Around the World [Yahoo! Finance]
11/18
07:40 pm
rckt
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $62.00 price target on the stock.
Medium
Report
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $62.00 price target on the stock.
11/18
11:06 am
rckt
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference [Yahoo! Finance]
Low
Report
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/7/2024
04:01 pm
rckt
rocket pharmaceuticals, inc.
BEAT
Report
1.2%
rocket pharmaceuticals, inc.
8/5/2024
04:01 pm
rckt
rocket pharmaceuticals, inc.
IN-LINE
Report
0.9%
rocket pharmaceuticals, inc.
5/6/2024
04:01 pm
rckt
rocket pharmaceuticals, inc.
BEAT
Report
0.7%
rocket pharmaceuticals, inc.
2/26/2024
04:01 pm
rckt
rocket pharmaceuticals, inc.
BEAT
Report
3.2%
rocket pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/21
04:27 pm
rckt
Form 144 ROCKET PHARMACEUTICALS, Filed by: Patel Kinnari
High
Report
Form 144 ROCKET PHARMACEUTICALS, Filed by: Patel Kinnari
11/21
04:07 pm
rckt
Form 144 ROCKET PHARMACEUTICALS, Filed by: Militello John
High
Report
Form 144 ROCKET PHARMACEUTICALS, Filed by: Militello John
11/21
03:58 pm
rckt
Form 144 ROCKET PHARMACEUTICALS, Filed by: Wilson Martin
Neutral
Report
Form 144 ROCKET PHARMACEUTICALS, Filed by: Wilson Martin
11/21
03:28 pm
rckt
Form 144 ROCKET PHARMACEUTICALS, Filed by: Shah Gaurav
Low
Report
Form 144 ROCKET PHARMACEUTICALS, Filed by: Shah Gaurav
11/18
04:16 pm
rckt
Form 8-K ROCKET PHARMACEUTICALS, For: Nov 18
Medium
Report
Form 8-K ROCKET PHARMACEUTICALS, For: Nov 18
11/8
10:53 am
rckt
Form SC 13G/A ROCKET PHARMACEUTICALS, Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SC 13G/A ROCKET PHARMACEUTICALS, Filed by: WELLINGTON MANAGEMENT GROUP LLP
11/7
04:51 pm
rckt
Form 10-Q ROCKET PHARMACEUTICALS, For: Sep 30
Low
Report
Form 10-Q ROCKET PHARMACEUTICALS, For: Sep 30
11/7
04:28 pm
rckt
Form 8-K ROCKET PHARMACEUTICALS, For: Nov 07
Medium
Report
Form 8-K ROCKET PHARMACEUTICALS, For: Nov 07
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease
32.9%
12/6 Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia 12.8%
9/11 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at William Blair. 12.7%
10/15 Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress 8.2%
12/13 Rocket Pharmaceuticals Announces Closing of Public Offering 7.3%
9/6 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at William Blair. 6.5%
4/2 Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day 6.5%
9/10 Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine 6.0%
9/4 Form 4 ROCKET PHARMACEUTICALS, For: Sep 02 Filed by: Militello John 5.8%
2/11 Form 8-K ROCKET PHARMACEUTICALS, For: Feb 10 5.2%
12/6 Rocket Pharmaceuticals Announces First Patient Treated in Global Registrational Phase 2 Study of RP-L102 “Process B” for Fanconi Anemia 12.8%
9/11 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at William Blair. 12.7%
10/15 Rocket Pharmaceuticals Announces Upcoming Presentations at the European Society of Gene and Cell Therapy Annual Congress 8.2%
12/13 Rocket Pharmaceuticals Announces Closing of Public Offering 7.3%
9/6 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at William Blair. 6.5%
4/2 Rocket Pharmaceuticals Announces Participation at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day 6.5%
9/10 Rocket Pharmaceuticals Announces Publication of Data from Phase 1/2 Trial of First-Generation RP-L102 for Fanconi Anemia in Nature Medicine 6.0%
9/4 Form 4 ROCKET PHARMACEUTICALS, For: Sep 02 Filed by: Militello John 5.8%
2/11 Form 8-K ROCKET PHARMACEUTICALS, For: Feb 10 5.2%
TOP News Decliners
3/12
Rocket Pharmaceuticals Inc (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $33.00 price target on the stock.
-20.5%
12/10 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock -14.0%
3/11 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -12.4%
3/26 Form 4 ROCKET PHARMACEUTICALS, For: Mar 24 Filed by: Shah Gaurav -9.5%
3/6 Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31 -7.8%
3/17 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.9%
5/22 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.2%
9/26 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is now covered by analysts at Piper Jaffray Companies. They set an "overweight" rating on the stock. -4.9%
4/1 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.7%
3/5 Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights -4.6%
12/10 Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock -14.0%
3/11 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock. -12.4%
3/26 Form 4 ROCKET PHARMACEUTICALS, For: Mar 24 Filed by: Shah Gaurav -9.5%
3/6 Form 10-K ROCKET PHARMACEUTICALS, For: Dec 31 -7.8%
3/17 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.9%
5/22 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.2%
9/26 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is now covered by analysts at Piper Jaffray Companies. They set an "overweight" rating on the stock. -4.9%
4/1 Rocket Pharmaceuticals Inc (NASDAQ: RCKT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.7%
3/5 Rocket Pharmaceuticals Reports Full Year 2019 Financial Results and Operational Highlights -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: